Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Denise A Yardley

1,2
1Sarah Cannon Research Institute, Nashville, TN, USA; 2Tennessee Oncology, Nashville, TN, USA

Abstract: There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer.

Keywords: breast cancer, bone metastases, hormone receptor-positive, bone-related complications, interventions, management and management strategies, estrogen receptor-positive

Introduction

Excluding skin cancers, breast cancer is the most frequently diagnosed cancer in US women; it is estimated that breast cancer will be diagnosed in more than 246,600 women in 2016 and that more than 40,450 will eventually die from their disease.1 Although the 5-year survival rate of patients with localized breast cancer is high (99%), the 5-year survival rate of patients with distant metastatic disease is 26%.2

Approximately 70% of breast cancers are hormone receptor-positive (HR+)3; for these, antiestrogen treatment strategies are recommended. Third-generation aromatase inhibitors (AIs) are standard first-line treatment for postmenopausal women with HR+ early or advanced breast cancer.4 AIs have demonstrated improvements in progression-free survival (PFS) and time to progression but have demonstrated only modest benefits in overall survival (OS) versus other endocrine therapies, including tamoxifen.5–9 Unfortunately, endocrine therapies have limited long-term efficacy due to development of resistance.10–12

Exemestane is a steroidal AI that was initially approved as first-line treatment for postmenopausal women with advanced breast cancer; it is also indicated for the treatment of those with disease progression following tamoxifen therapy.13 Based on evidence of increased signaling through the PI3K/AKT/mammalian target of rapamycin pathway in hormone-resistant metastatic breast cancer (MBC),14–16 the combination of exemestane
plus everolimus, a mammalian target of rapamycin inhibitor, as a treatment for advanced breast cancer has been explored. Results of the Phase III Breast Cancer Trials of Oral Everolimus-2 (BOLORE-2) demonstrated that everolimus plus exemestane was effective in prolonging PFS, leading to approval in postmenopausal women with HR+/human epidermal growth factor receptor 2-negative advanced breast cancer following progression on nonsteroidal AIs.4,17–19 Other US Food and Drug Administration-approved agents have also been effective as monotherapy in tumors exhibiting disease progression. Based on results from the Phase III Evaluation of Faslodex versus Exemestane Clinical Trial and Comparison of Faslodex in Recurrent or Metastatic Breast Cancer studies,20,21 monotherapy with fulvestrant, a selective estrogen receptor downregulator, has been approved for postmenopausal women with HR+ MBC whose disease progressed on previous endocrine therapies.22 Other combination endocrine strategies, including the cyclin-dependent kinase 4/6 inhibitors, are under evaluation for patients with endocrine-resistant MBC.23,24 Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was recently approved for use in combination with letrozole, but only as initial endocrine-based therapy in patients with MBC.23,24

Given that 61 years is the median age at initial diagnosis of all-stage breast cancer;7 many postmenopausal women with diagnoses of breast cancer may already have age-associated bone loss and may require or have been initiated on pharmacologic interventions. Patients with breast cancer are at increased risk for bone loss and fracture compared with age-matched women without cancer.25 Additionally, evidence suggests that both chemotherapeutic and antiestrogen agents, to which many patients have been exposed during the disease course, contribute to detrimental bone effects;26,27 this is most notable with endocrine therapies, such as AIs and even tamoxifen, which are known to exacerbate bone-related complications because they may increase bone mineral loss.28–30 These observations highlight the need to effectively manage bone-related complications in postmenopausal women with HR+ breast cancer.

This review discusses the current understanding of molecular mechanisms involved in bone turnover and metastases, increased risk for bone-related complications as a result of age and breast cancer, therapies used to treat breast cancer, and current and emerging treatment strategies for managing bone metastases and bone turnover.

**Current understanding of bone biology and breast cancer**

Bone is continually remodeled by interactions among bone matrix-producing osteoblasts, bone resorption-associated osteoclasts, and resident bone osteocytes.31 Estrogen depletion, which occurs in menopause and breast cancer, induces preosteoblasts and osteocytes to secrete the receptor activator of nuclear factor-kappa B ligand (RANK-L), resulting in activation of osteoclast precursors and mature osteoclasts.31–33 Activated osteoclasts accelerate bone resorption and remodeling, causing increased bone turnover.31–33

Bone remodeling in patients with bone MBC predominantly uses activated osteoclasts mainly involving RANK-L, parathyroid hormone-related peptide, osteoprotegrin (OPG), and transforming growth factor beta.34,35 When tumor cells invade bone, they produce parathyroid hormone-related peptide, which in turn stimulates the upregulation of RANK-L expression by preosteoblasts and downregulates the expression of OPG (OPG normally acts to inhibit RANK-L function); this drives the stimulation of osteoclasts and leads to excessive bone resorption and destruction.34,35 Tumor cells also secrete a number of other factors that increase osteoclast formation, including interleukin-6, prostaglandin E2, tumor necrosis factor, and macrophage colony-stimulating factor.35 These additional factors further increase RANK-L expression, resulting in RANK-L acting on osteoclast precursors to increase osteoclast production.35 Osteoclastic activity in turn increases the production of factors that increase parathyroid hormone-related peptide production, including but not exclusive to transforming growth factor beta, insulin-like growth factors, platelet-derived growth factor, and bone morphogenetic proteins.35 Therefore, the increased RANK-L/OPG ratio activates osteoclasts and bone resorption while releasing the growth factors from the bone matrix that can stimulate tumor growth.34,35 Consequently, tumor cells and osteoclasts engage in a self-perpetuating cycle, increasing bone absorption and tumor growth.34,35 In patients with bone metastases, increased RANK-L can increase bone destruction and result in significant skeletal-related events (SREs), such as spinal cord compression and pathologic fractures.34 Bone is the predominant, and often the first, site of breast cancer metastasis; 50% to 70% of women who experience metastases present with bone metastases during their disease course.34,36,37 Bone metastases often occur in load-bearing bones and patients are therefore at an increased risk of bone fracture if they develop in the femoral neck and shaft or the pelvis.36 Other consequences of bone metastases include bone deformity with vertebral body collapse or compression, hypercalcemia, leukoerythroblastic anemia, and nerve compression syndromes, such as spinal cord compression, that can lead to pain, debilitation, and kyphosis.36
Bone-related complications caused by treatment

Osteoporosis affects 200 million women worldwide and is responsible for more than 8.9 million fractures annually; one in three women aged >50 years will experience an osteoporotic fracture.\textsuperscript{38,39} The incidence of this disease increases with age in women, affecting ~10%, 20%, 40%, and 67% of those aged 60, 70, 80, and 90 years, respectively.\textsuperscript{38} Bone mineral density (BMD) scans, known as dual-energy x-ray absorptiometry scans, are used to diagnose osteoporosis. The US Preventive Services Task Force recommends dual-energy x-ray absorptiometry scans for those aged ≥65 years,\textsuperscript{40} although many women are diagnosed with breast cancer prior to reaching this age. Changes in bone turnover markers are used to monitor osteoporosis treatment. BAP, a glycoprotein attached to the surface of osteoblasts, and procollagen type I N-terminal propeptide (PINP), a peptide secreted by osteoblasts, are markers routinely used to measure osteoblastic activity, whereas C-terminal telopeptide (CTX) is a peptide cleaved by osteoclasts and a common marker for bone resorption.\textsuperscript{41}

The personal and economic toll of osteoporosis is evident in Europe, where disability due to osteoporosis is greater than that caused by cancers (with the exception of lung cancer).\textsuperscript{39} These findings are loosely paralleled in the US population, where the average length of stay in hospital in 2010 was greater for patients suffering from osteoporotic-related fractures in the neck of the femur (5.8 days on average) compared to that for heart disease (4.6 days), myocardial infarction (5.4 days), and diabetes (4.6 days).\textsuperscript{42} In line with these data, osteoporosis and osteopenia are considered major public health threats for nearly 44 million women and men aged ≥50 years in the USA.\textsuperscript{43} The impact of a timely and effective breast cancer diagnosis and its subsequent treatment can thus be significant in helping to ameliorate the patient’s risks associated with osteoporosis and reduce the incidence of general bone health-related issues in breast cancer.

AIs deplete circulating estrogen\textsuperscript{44} and can negatively impact bone remodeling; this decreases BMD and increases bone loss,\textsuperscript{45} which is estimated to be twofold greater than menopause-related bone loss.\textsuperscript{46–48} The consequences of decreased BMD and increased bone loss as a result of AI therapy include greater risk for osteoporosis and bone fractures\textsuperscript{30,46,49–51} and potentially increased risk for morbidity and mortality.\textsuperscript{52} Adjuvant studies confirm that AIs increase fracture risk, with an incidence of 7% after a median of 30 months of treatment with exemestane and an incidence of 9% to 11% after up to 5 years of treatment with letrozole or anastrozole.\textsuperscript{50,53,54}

Other endocrine agents used in the treatment of breast cancer differ from AIs in their impact on bone. Possibly because of its estrogenic agonistic effects, tamoxifen has been shown to improve BMD in postmenopausal women,\textsuperscript{45,55,56} but similar effects in premenopausal women are not seen.\textsuperscript{37} Few results have been reported with fulvestrant; however, in a small 18-month substudy that included 14 patients treated with fulvestrant as first-line therapy in locally advanced breast cancer, fulvestrant did not increase the bone turnover markers BAP, PINP, and CTX.\textsuperscript{59} Given the small number of patients in this trial, it is unclear what impact the seemingly bone-neutral effects of fulvestrant might have in countering or not worsening detrimental bone loss experienced with earlier adjuvant therapies, but it is worth additional exploration.

Pharmacologic interventions to manage bone-related complications

Therapies decreasing bone resorption or stimulating new bone formation include bisphosphonates and the monoclonal antibody to human RANK-L.\textsuperscript{59–61} Bisphosphonates are a class of drugs that bind bone minerals where they are absorbed by mature osteoclasts; this results in osteoclast apoptosis and suppression of bone resorption.\textsuperscript{31} Use of bisphosphonates in other cancer types, such as osteolytic disease in multiple myeloma and metastatic bone disease in other solid tumors, is increasingly common, particularly to prevent skeletal complications, relieve bone pain, and prevent treatment-induced bone loss.\textsuperscript{34} Denosumab is a monoclonal antibody that binds to human RANK-L and prevents osteoclast formation, function, and survival and reduces cancer-induced bone destruction.\textsuperscript{32} The optimal pharmacologic management of bone-related complications in breast cancer is debated, but it is largely derived from clinician experiences with these complications in aging and osteoporosis.\textsuperscript{62}

In early breast cancer, postmenopausal women who initiate adjuvant therapy with AIs often receive calcium and vitamin D supplements, and additional bisphosphate therapy is considered to avoid a progression to osteoporosis in patients with osteopenia.\textsuperscript{63} High weekly doses of vitamin D\textsubscript{2} or D\textsubscript{3} are effective at reducing AI-induced musculoskeletal symptoms when given after the initiation of AI therapy.\textsuperscript{54,65} Bisphosphonates reduce AI-induced bone loss and improve BMD in patients with early breast cancer.\textsuperscript{66–71} Similarly, denosumab improves BMD in postmenopausal women with early breast cancer who are undergoing adjuvant AI therapy.\textsuperscript{72} The bisphosphonates zoledronate and pamidronate and the
RANK-L inhibitor denosumab are approved for the treatment of advanced breast cancer and bone metastases\textsuperscript{59-61} and are recommended for the prevention and treatment of SREs.\textsuperscript{4,73}

**Bisphosphonates**

In the Phase III Protocol 19 trial of the Aredia Breast Cancer Study Group in women with MBC who had previously received chemotherapy, pamidronate prolonged median time to first skeletal complication versus placebo (13.9 vs 7.0 months; \textit{P}>0.001).\textsuperscript{74} The Phase II Protocol 18 trial from the same group demonstrated that pamidronate decreased skeletal morbidity rate and increased time to first SRE versus placebo, and a sustained reduction in bone turnover markers (ie, urinary calcium, hydroxyproline, creatinine, and serum bone alkaline phosphatase) was achieved with pamidronate.\textsuperscript{75} There were no differences in adverse effects between the placebo and drug groups in the use of pamidronate.\textsuperscript{74,75} Anemia, thrombocytopenia, hyperphosphatemia, myalgias, arthralgias, and influenza-like symptoms were slightly higher in the pamidronate group.\textsuperscript{74} Other trials found that vomiting and fatigue were the only adverse effects that were slightly higher in the pamidronate group than the placebo group.\textsuperscript{75} None of these differences reached a level of statistical significance.\textsuperscript{74,75}

Similarly, zoledronate reduced skeletal complications in a randomized, placebo-controlled registration trial in Japanese women with breast cancer-related bone metastases.\textsuperscript{76} Compared with placebo, zoledronate reduced the risk for SREs at 1 year by 39\% (\textit{P}=0.027).\textsuperscript{76} Median time to first SRE was significantly longer for zoledronate recipients than placebo recipients (not reached vs 364 days; \textit{P}=0.007).\textsuperscript{76} Tolerability of zoledronate was within the same safety profile as placebo, with less than a 15\% frequency of reported adverse events by any group.\textsuperscript{76} The most frequent adverse events suspected to be drug-related were pyrexia, nausea, and fatigue.\textsuperscript{76} Direct comparison of zoledronate with pamidronate in a Phase III trial of patients with bone MBC demonstrated no significant difference in the incidence of SREs.\textsuperscript{77} However, a subgroup analysis of patients with at least one osteolytic lesion at study entry suggested zoledronate was superior to pamidronate in reducing skeletal complications.\textsuperscript{77} Data for other bisphosphonates not licensed in the USA for use in patients with breast cancer are also available; in particular, they show that ibandronate reduced the risk for vertebral fractures and new bone events, and reduced the skeletal morbidity period rate (defined as 12-week periods without new SREs) versus placebo in Phase III trials in patients with bone metastases from breast cancer.\textsuperscript{79,80}

**Monoclonal antibody to RANK-L**

In a Phase III trial in patients with advanced breast cancer with at least one bone metastasis, denosumab was found to be superior to zoledronate in delaying or preventing SREs (hazard ratio, 0.82; \textit{P}=0.01).\textsuperscript{81} Bone turnover markers were also suppressed to a greater extent with denosumab than with zoledronate (\textit{P}>0.001).\textsuperscript{81} Reported adverse events were similar between treatment groups where the most serious adverse event reported was anemia (5.7\% of patients). The denosumab group reported a higher incidence of hypocalcemia than the zoledronate group, while the latter group reported a higher incidence of adverse renal events and acute phase reactions.\textsuperscript{82} The discontinuation of denosumab showed that its effects on BMD and bone turnover markers are fully reversible and able to be restored with retreatment when no increase in fracture risk was observed after discontinuation.\textsuperscript{83-85} Furthermore, patients receiving denosumab were found to exhibit higher BMD than patients in the corresponding placebo group.\textsuperscript{83,84} Consistent with these data, a meta-analysis of several randomized trials comparing bisphosphonates with placebo, bisphosphonates with other bisphosphonates, and bisphosphonates with denosumab supports the role of bisphosphonates and denosumab in reducing the risk for SREs in patients with breast cancer-related bone metastases, and indicates that these therapies were also effective in delaying the time to SREs.\textsuperscript{84}

**Everolimus/Exemestane combination**

Everolimus was approved in combination with exemestane for postmenopausal women with HR+/HER2– advanced breast cancer that progressed on previous nonsteroidal AI therapy.\textsuperscript{17} Exemestane reportedly increases bone resorption,\textsuperscript{86} though a preclinical study suggested that everolimus directly inhibits bone resorption by osteoclasts.\textsuperscript{87} Based on these insights, an exploratory analysis of the BOLERO-2 trial data was performed to evaluate bone turnover markers.\textsuperscript{88} Results showed increased bone turnover marker levels in exemestane recipients at 6 and 12 weeks compared with baseline, whereas bone turnover marker levels decreased in everolimus plus exemestane recipients.\textsuperscript{88} Bone-related adverse events, including fractures, osteonecrosis, and osteoporosis, were similar between treatment groups where the safety profile was acceptable and manageable.\textsuperscript{88} These observations suggest that everolimus may prevent bone turnover associated with AI therapy, but this should be verified in prospective studies.

To further investigate the long-term effects of everolimus on bone health, the Phase IIb study in postmenopausal women with HR+ advanced breast cancer treated with everolimus
plus exemestane was recently completed (NCT01626222) (Table 1).\textsuperscript{89,90} Primary end point was overall response rate after 6 months. Secondary end points included PFS after 6 and 12 months, overall response rate after 12 months, OS, quality of life, health utilities, and health care resources. Exploratory objectives included assessment of bone turnover biomarkers (ie, PINP, CTX, OPG, RANK-L, vitamin D, follicle-stimulating hormone, and estradiol). Preliminary exploratory data on bone biomarkers suggest that everolimus reduces bone turnover and reverses the increase in bone absorption associated with endocrine therapy.\textsuperscript{89} The ability of everolimus to reduce bone resorption could be linked to its antitumor properties or everolimus may have a direct effect on AI-induced bone resorption; however, additional analyses of the data are needed to confirm the finding.\textsuperscript{88}

**Investigational agents**

Other therapies currently under investigation include the small molecule tyrosine kinase inhibitors vandetanib (vascular endothelial growth factor receptor and epidermal growth factor receptor receptor), dasatinib (breakpoint cluster region–Abelson murine leukemia and Src), and cabozantinib (c-MET and vascular endothelial growth factor receptor 2). Data are available only for vandetanib, which was evaluated in a Phase II trial of postmenopausal women with bone-only or bone-predominant HR+ MBC, and demonstrated that adding vandetanib to fulvestrant did not improve biomarker response, PFS, or OS versus fulvestrant alone (NCT00811369).\textsuperscript{91} At least two Phase II trials with secondary end points of bone turnover are evaluating dasatinib in combination with endocrine therapy. Results are eagerly awaited for a completed Phase II trial (NCT00754325) evaluating dasatinib in combination with fulvestrant in patients with HR+ advanced breast cancer previously treated with an AI. In the second trial (NCT00696072), final efficacy results demonstrated that dasatinib as first- or second-line therapy with letrozole in postmenopausal women with HR+/HER2− breast cancer did not appear to improve clinical benefit rate (primary end point) but it prolonged PFS.\textsuperscript{92} Cabozantinib is under evaluation in a Phase II trial (NCT01441947) in women with HR+ MBC with bone involvement, with bone imaging response rate the primary end point and bone turnover a secondary end point.

**Antitumor effects of bone-modifying agents in patients with breast cancer**

Although bone-modifying agents are used as supplementary therapy to prevent or reduce the incidence of SREs in patients with malignant bone disease, recent evidence from multiple myeloma and other solid tumors suggests that these agents may also demonstrate antitumor activity.\textsuperscript{93} Preliminary evidence of the effects of these agents in delaying disease

---

**Table 1** Summary of compounds in development for the management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

<table>
<thead>
<tr>
<th>Agent</th>
<th>Clinical trial identifier</th>
<th>Phase</th>
<th>Design</th>
<th>End points</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>mTOR inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Everolimus</td>
<td>EVE NCT01626222</td>
<td>IIIb</td>
<td>EVE+EXE vs PBO+EXE in patients with ABC or MBC</td>
<td>Primary: ORR</td>
<td>Completed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exploratory: Bone turnover markers</td>
<td></td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>NCT01441947</td>
<td>II</td>
<td>CAB+FUL in HR+ BC that has spread to the bone</td>
<td>Primary: Bone imaging response rate</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Bone turnover</td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>NCT00754325</td>
<td>II</td>
<td>DAS+FUL in patients with ABC</td>
<td>Primary: PFS</td>
<td>Completed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Change in bone markers, effect on bone pain, BMD changes</td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>NCT00696072</td>
<td>II</td>
<td>DAS+LET vs LET in MBC</td>
<td>Primary: CBR</td>
<td>Completed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Change in bone markers, effect on bone pain, BMD changes</td>
<td></td>
</tr>
<tr>
<td>Vandetanib</td>
<td>NCT00811369</td>
<td>II</td>
<td>VAN+FUL vs PBO+FUL in patients with bone only or bone-predominant HR+ MBC</td>
<td>Primary: Change in NTx level</td>
<td>Completed</td>
</tr>
</tbody>
</table>

**Abbreviations:** ABC, advanced breast cancer; BC, breast cancer; BMD, bone mineral density; CAB, cabozantinib; CB, clinical benefit rate; DAS, dasatinib; EVE, everolimus; EXE, exemestane; FUL, fulvestrant; HR+, hormone receptor-positive; LET, letrozole; MBC, metastatic breast cancer; mTOR, mammalian target of rapamycin; NTx, N-terminal telopeptide; ORR, overall response rate; PBO, placebo; PFS, progression-free survival; VAN, vandetanib.
progression in patients with early breast cancer is emerging,⁹⁴ and initial reports of their antitumor effects in advanced disease are available.⁹⁵,⁹⁶

Results from preclinical studies provide a potential mechanism for antitumor activity.⁴⁸ Preclinical evidence suggests that the nitrogen-containing bisphosphonates zoledronate and pamidronate block the enzyme farnesyl diphosphatase synthase, resulting in inhibition of tumor cell adhesion, migration, invasion, and proliferation and inducing cell death in a wide range of cell lines.⁹⁷ Nitrogen-containing bisphosphonate-mediated reductions in skeletal tumor burden in animal models have been attributed to their antiresorptive activity because they deprive tumor cells of growth factors required for seeding and growth of tumor cells in the bone marrow.⁹⁸,⁹⁹

Studies of bisphosphonates in the treatment of early breast cancer provide conflicting evidence for a potential antitumor effect, with improvements in disease-free survival (DFS), OS, or both observed in some studies and either no effect or a detrimental effect observed in others.⁶⁷,⁹⁴,⁹⁶,¹⁰⁰–¹⁰⁴ Recent meta-analyses have indicated a positive effect of adjuvant bisphosphonate therapy on DFS, bone recurrence, OS, and breast cancer-specific survival in postmenopausal women.¹⁰⁵–¹⁰⁷ These findings are corroborated by Early Breast Cancer Trialists’ Collaborative Group et al.,¹⁰⁸ which noted that adjuvant bisphosphonate therapies significantly reduce bone recurrence while subgroup analyses demonstrated this benefit in postmenopausal women only with the additional benefit of significantly reducing distant recurrence, breast cancer mortality, and overall mortality. These reductions were apparent regardless of chemotherapy status, suggesting bisphosphonates to be additive to chemotherapy and vice versa. The effect of different bisphosphonate regimens remains unclear.¹⁰⁸

In contrast, a Cochrane review based on a meta-analysis of seven randomized trials in early breast cancer indicated insufficient evidence to arrive at a conclusion regarding the efficacy of bisphosphonates in reducing the incidence of bone metastases or improving survival.²⁴ Denosumab is under evaluation in two Phase III trials (NCT01077154 and NCT00556374) as neoadjuvant and adjuvant therapy for up to 5 years in women with high-risk early breast cancer. Both trials include DFS, OS, and bone metastasis-free survival as end points.

Data on the antitumor effects of bone-modifying agents in advanced breast cancer are less extensive than they are in earlier disease. In a recent study of breast cancer patients with bone marrow-detected tumor cells, zoledronate was more effective than placebo in eliminating these cells.¹⁰⁹ In a randomized trial of patients with early-stage breast cancer with identified tumor cells in the bone marrow, the risk for distant metastases was significantly lower with adjuvant clodronate than standard follow-up (13% vs 29%; \( P<0.001 \)), as was the incidence of osseous and visceral metastases (8% vs 17% and 8% vs 19%, respectively; \( P=0.003 \) for both).⁹⁵

Although the bone-protective effects of everolimus remain to be confirmed, initial reports of its antitumor effects on bone metastases are available. In a Phase II hypothesis-generating study, everolimus single-agent activity on bone metastases was noted in patients whose bone metastases had not progressed after 8 weeks of treatment.¹¹⁰ This randomized, double-blind, placebo-controlled, Phase II study demonstrated that treatment continuation with everolimus was beneficial in patients with HER2− breast cancer and bone metastases.¹¹¹ An exploratory analysis of results from the BOLERO-2 trial showed that progressive disease in bone occurred in 13.0% of patients treated with everolimus plus exemestane versus 18.8% treated with exemestane alone.⁸⁸ The median PFS in patients with bone-only metastasis treated with everolimus plus exemestane and exemestane alone was 12.9 and 5.3 months, respectively, translating to a 67% reduction in risk of progression with everolimus therapy (hazard ratio, 0.33; \( P<0.05 \)).¹¹² This reduction in risk of progression was similar to the 55% reduction in risk of progression observed in the overall population of the trial at a median follow-up of 18 months (hazard ratio, 0.45; \( P<0.0001 \)).¹¹² These findings suggest that everolimus may help lower disease progression in bone, but larger prospective trials are needed to confirm this observation.

Complications of treatment with bone-modifying agents

Nephrotoxicity, hypocalcemia, and osteonecrosis of the jaw (ONJ) are some clinically important adverse events observed with bone-modifying agents.¹¹² Nephrotoxicity typically manifests as serum creatinine elevations, occurring in 2% to 8% of patients treated with intravenous bisphosphonates¹¹² and in 0% to 5% of those treated with denosumab.⁸¹ Risk for nephrotoxicity is increased in patients with preexisting renal dysfunction, and bisphosphonates are not recommended for patients with creatinine clearance less than 30 mL/min.¹¹³ Hypocalcemia occurs in up to 5% of patients treated with bisphosphonates or denosumab; therefore, calcium and vitamin D supplementation and regular monitoring of serum calcium are recommended for these patients.¹¹² ONJ is a
rare but distressing complication, reported in 1.2% to 2.4% of patients treated with bisphosphonates and ~2% of patients treated with denosumab. Risk factors for ONJ include use of high-potency aminobisphosphonates (ie, nitrogen-containing bisphosphonates that have significantly increased antiresorptive potencies compared to non-nitrogen-containing bisphosphates), prolonged treatment, concurrent chemotherapy, underlying dental disease, and invasive dental procedures; the incidence of ONJ may be as high as 10% in patients with multiple risk factors. Risk for ONJ may be mitigated by pretreatment dental assessments (with any required interventions completed before treatment initiation), limitation of dental and jaw bone trauma during treatment, and regular dental monitoring. Additionally, intravenous bisphosphonates are associated with acute-phase reactions consisting of fever, myalgia, bone pain, and fatigue in up to a third of patients; these reactions typically resolve within 72 hours and can be managed with supportive measures. Conversely, oral bisphosphonates are associated with significant gastrointestinal toxicity (ie, nausea, vomiting, epigastric pain, and esophagitis).

Conclusion

Although postmenopausal women with HR+ breast cancer have a better prognosis than postmenopausal women with other breast cancer subtypes, they are at high risk for bone loss and SREs. The efficacy of bisphosphonates in preventing bone loss with chemotherapy and AI therapy in both premenopausal and postmenopausal women has been demonstrated. Although the effect of adding bisphosphonates to neoadjuvant chemotherapy regimens to improve clinical outcomes is unclear, previous studies suggest that the use of bisphosphonates in this setting may have a positive effect on pathological response. Direct comparison of available agents is limited by variations in dosing across studies and requires further investigation.

Bone-modifying agents, including bisphosphonates and denosumab, are recommended as supplementary therapies for minimizing bone remodeling and increasing bone mass in patients at high risk for fracture. Given that 61 years is the median age of women at initial diagnosis of breast cancer, a substantial portion of these patients will already be experiencing normal age-related effects of bone loss. Results from clinical trials investigating the antitumor effects of antiresorptive therapies have been conflicting but generally support a small absolute improvement in OS, with the largest treatment impact on reductions in the recurrence of bone metastasis.

These observations highlight the need for novel therapies that are effective in minimizing bone loss, preventing new bone metastases, and improving the outcomes of patients with HR+ breast cancer. In order to achieve these goals in postmenopausal women with HR+ advanced breast cancer, oncologists should carefully assess the safety and efficacy of agents that protect and prevent disease progression in the bone to appropriately incorporate them into treatment regimens.

Acknowledgments

Tricia Newell, PhD, and Matthew Grzywacz, PhD (ApotheCom, Yardley, PA, USA), provided writing and editorial assistance that supported the author in the development of this manuscript. This writing and editorial assistance was funded by Novartis Pharmaceuticals Corporation.

Disclosure

Denise A. Yardley, MD, serves as a consultant to Novartis Pharmaceuticals Corporation. The author reports no other conflicts of interest in this work.

References

Managing bone-associated complications in postmenopausal breast cancer


78. Hadji P, Tesch H, Fasching PA, et al. 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)? Presented at: San Antonio Breast Cancer Symposium; December 14, 2013; San Antonio, TX, USA; abstr P6-06-32rt.
90. Tesch H, Fasching PA, Hadji P, et al. 4EVER – A phase IIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE). Presented at: San Antonio Breast Cancer Symposium; December 12, 2013; San Antonio, TX, USA; abstr OT2-69.


